What’s the consensus on RU58841 vs Pyrilutamide (Kx-826)? 3/27/2026
RU58841 and Pyrilutamide (Kx-826) are both topical anti-androgens, but neither is effective for hair regrowth. RU58841 has more anecdotal support, while Pyrilutamide has progressed further in trials, though both have limitations.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity KX-826 and RU58841: do topical anti-androgens work?
KX-826 and RU58841 are topical anti-androgens discussed for hair loss prevention, with KX-826 showing promise in trials and RU58841 having mixed anecdotal results. Users report combining these with treatments like minoxidil, finasteride, and dutasteride, with varying success and concerns about side effects.
community Consenus on Kx-826/pyrilutamide vs ru58841
KX-826 is considered effective for hair maintenance, with better safety research than RU58841, but lacks positive anecdotes. RU58841 is seen as potentially stronger, but concerns exist about systemic effects; combining anti-androgens with 5AR inhibitors is suggested for better results.
community Choose your topical antiandrogen and tell me why
The conversation is about choosing a topical antiandrogen for hair loss, with options including RU58841, CB0301, Pyrolutamide, Alfatradiol, and Fluridil. Users discuss their preferences and reasons for selecting specific treatments.
community Breezula is the final brick in the wall
Breezula is discussed as a potential topical anti-androgen treatment for hair loss, with mixed opinions on its effectiveness and side effects compared to other treatments like finasteride, minoxidil, and RU58841. Some users express skepticism about its long-term efficacy and potential side effects, while others are hopeful for its approval and use in combination with existing treatments.
community Waiting to start treatment until Kintor KX-826 Phase 2 data is published?
People are waiting for KX-826 (Pyrilutamide) Phase 2 data to decide on hair loss treatments, with some considering finasteride or minoxidil in the meantime. Pyrilutamide is seen as a potentially stronger and safer alternative to finasteride, but concerns about side effects and availability remain.
Related Research
6 / 6 results
research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
research RU 58841, a new specific topical antiandrogen: A candidate of choice for the treatment of acne, androgenetic alopecia and hirsutism
This study found that the topically applied non-steroidal antiandrogen RU 58841 may reduce androgen-dependent skin conditions in a hamster model with minimal systemic effects.
research RU 58841-myristate–prodrug development for topical treatment of acne and androgenetic alopecia.
This study reports that RU 58841-myristate, a new antiandrogen prodrug formulated with solid lipid nanoparticles, shows potential for targeting hair follicles in preclinical laboratory settings.
research A controlled study of the effects of RU58841, a non-steroidal antiandrogen, on human hair production by balding scalp grafts maintained on testosterone-conditioned nude mice
This study found that the non-steroidal antiandrogen RU58841 increased hair growth rates and promoted hair cycle initiation in balding human scalp grafts on testosterone-conditioned nude mice, indicating a positive effect on hair growth.
research Alternative synthesis of the anti-baldness compound RU58841
A new, less toxic and more efficient method to create the anti-baldness compound RU58841 was developed in 2014.
research Dose-dependent and long term effects of RU58841 (androgen receptor blocker) on hair growth in the bald stumptailed Macaque.
In this study using a macaque model, RU58841 at a 5% concentration significantly increased hair density, thickness, and length in the frontal bald scalp over six months.